GYRE THERAPEUTICS, INC. (GYRE) Executive Compensation
GYRE THERAPEUTICS, INC. (GYRE) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: GYRE
CIK: 1124105
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Grant Thornton Zhitong Certified Public Accountants LLP
Auditor SinceSince 12/31/2023 12:00:00 AM
Lead Engagement PartnerJingru Lu
Audit LocationBeijing, China
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 8-K | 2026-09-01 | 2026-09-01 | 8-K | 0001140361-26-035189 | View SEC Doc Filr Page |
| S-8 | 2026-08-27 | — | S-8 | 0001140361-26-034882 | View SEC Doc Filr Page |
| 8-K | 2026-08-26 | 2026-08-26 | 8-K | 0001140361-26-034401 | View SEC Doc Filr Page |
| 10-Q | 2026-08-07 | 2026-06-30 | 10-Q | 0001193125-26-340448 | View SEC Doc Filr Page |
| 8-K | 2026-08-07 | 2026-08-07 | 8-K | 0001193125-26-339223 | View SEC Doc Filr Page |
| 4 | 2026-08-04 | 2026-08-03 | FORM 4 | 0001140361-26-031326 | View SEC Doc Filr Page |
| 4 | 2026-08-04 | 2026-08-03 | FORM 4 | 0001140361-26-031324 | View SEC Doc Filr Page |
| 3 | 2026-08-04 | 2026-08-01 | FORM 3 | 0001140361-26-031322 | View SEC Doc Filr Page |
| 3 | 2026-08-04 | 2026-08-01 | FORM 3 | 0001140361-26-031320 | View SEC Doc Filr Page |
| EFFECT | 2026-08-03 | — | EFFECT Filing | 9999999995-26-002523 | View SEC Doc Filr Page |
| 8-K | 2026-07-16 | 2026-07-10 | 8-K | 0001140361-26-028716 | View SEC Doc Filr Page |
| 8-K/A | 2026-07-15 | 2026-05-04 | 8-K/A | 0001140361-26-028564 | View SEC Doc Filr Page |
| S-3/A | 2026-07-13 | — | S-3/A | 0001140361-26-028333 | View SEC Doc Filr Page |
| 4 | 2026-06-30 | 2026-06-10 | FORM 4 | 0001140361-26-027008 | View SEC Doc Filr Page |
| 4 | 2026-06-30 | 2026-06-10 | FORM 4 | 0001140361-26-027007 | View SEC Doc Filr Page |
| 4 | 2026-06-30 | 2026-06-10 | FORM 4 | 0001140361-26-027006 | View SEC Doc Filr Page |
| 4 | 2026-06-30 | 2026-06-10 | FORM 4 | 0001140361-26-027005 | View SEC Doc Filr Page |
| 4 | 2026-06-30 | 2026-06-10 | FORM 4 | 0001140361-26-027004 | View SEC Doc Filr Page |
| 4 | 2026-06-30 | 2026-06-10 | FORM 4 | 0001140361-26-027003 | View SEC Doc Filr Page |
| S-3 | 2026-06-23 | — | S-3 | 0001140361-26-025999 | View SEC Doc Filr Page |
| 4 | 2026-06-22 | 2026-06-09 | FORM 4 | 0001140361-26-025950 | View SEC Doc Filr Page |
| 8-K | 2026-06-16 | 2026-06-10 | 8-K | 0001140361-26-025324 | View SEC Doc Filr Page |
| 4 | 2026-06-15 | 2026-06-11 | FORM 4 | 0001140361-26-025208 | View SEC Doc Filr Page |
| 4 | 2026-06-11 | 2026-06-09 | FORM 4 | 0001140361-26-024929 | View SEC Doc Filr Page |
| 4 | 2026-06-10 | 2026-06-08 | FORM 4 | 0001140361-26-024785 | View SEC Doc Filr Page |